Tim Vollmer, MD

Professional Titles

• Vice Chair, Clinical Research
• Co-Director Rocky Mountain MS Center at Anschutz

Recognitions

• Physician of Distinction Award, Accelerated Cure Project for Multiple Sclerosis (2011)
  
• Best Doctors, Top 1% of neurologists ranked nationally, US News & World Report (2011)
  
• • Fellow, American Academy of Neurology 2009, American Academy of Neurology (2009)
  
• • University of Colorado Department of Neurology Teaching Award 2009, University of Colorado Residents (2009)
  

Publications

• Honce JM, Nair KV, Hoyt BD, Seale RA, Sillau S, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Alvarez E. Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. Front Neurol. 2020;11:1045. PubMed PMID: 33071934
• Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord. 2020 Aug 18;46:102454. [Epub ahead of print] PubMed PMID: 33045496
• Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 Aug 6. [Epub ahead of print] PubMed PMID: 32767538
• Engebretson E, Seale RA, Valdez B, Vollmer TL, Medina LD. Validation of the functional assessment of chronic illness therapy - General treatment satisfaction (FACIT-TS-G) in multiple sclerosis. Mult Scler Relat Disord. 2020 Oct;45:102413. PubMed PMID: 32731202
• Cudkowicz M, Chase MK, Coffey CS, Ecklund DJ, Thornell BJ, Lungu C, Mahoney K, Gutmann L, Shefner JM, Staley KJ, Bosch M, Foster E, Long JD, Bayman EO, Torner J, Yankey J, Peters R, Huff T, Conwit RA, Shinnar S, Patch D, Darras BT, Ellis A, Packer RJ, Marder KS, Chiriboga CA, Henchcliffe C, Moran JA, Nikolov B, Factor SA, Seeley C, Greenberg SM, Amato AA, DeGregorio S, Simuni T, Ward T, Kissel JT, Kolb SJ, Bartlett A, Quinn JF, Keith K, Levine SR, Gilles N, Coyle PK, Lamb J, Wolfe GI, Crumlish A, Mejico L, Iqbal MM, Bowen JD, Tongco C, Nabors LB, Bashir K, Benge M, McDonald CM, Henricson EK, Oskarsson B, Dobkin BH, Canamar C, Glauser TA, Woo D, Molloy A, Clark P, Vollmer TL, Stein AJ, Barohn RJ, Dimachkie MM, Le Pichon JB, Benatar MG, Steele J, Wechsler L, Clemens PR, Amity C, Holloway RG, Annis C, Goldberg MP, Andersen M, Iannaccone ST, Smith AG, Singleton JR, Doudova M, Haley EC, Quigg MS, Lowenhaupt S, Malow BA, Adkins K, Clifford DB, Teshome MA, Connolly N. Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurol. 2020 Jun 1;77(6):755-763. PubMed PMID: 32202612
• Graner M, Pointon T, Manton S, Green M, Dennison K, Davis M, Braiotta G, Craft J, Edwards T, Polonsky B, Fringuello A, Vollmer T, Yu X. Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides. PLoS One. 2020;15(2):e0228883. PubMed PMID: 32084151
• Vollmer B, Ontaneda D, Harris H, Nair K, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019 Dec 15;407:116498. PubMed PMID: 31644992
• Wolf AB, Ryerson LZ, Pandey K, McGettigan BM, Vollmer T, Corboy JR, Alvarez E. Rituximab-induced serum sickness in multiple sclerosis patients. Mult Scler Relat Disord. 2019 Nov;36:101402. PubMed PMID: 31542710
• Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2019 Feb;6(2):252-262. PubMed PMID: 30847358
• Kletenik I, Alvarez E, Honce JM, Valdez B, Vollmer TL, Medina LD. Subjective cognitive concern in multiple sclerosis is associated with reduced thalamic and cortical gray matter volumes. Mult Scler J Exp Transl Clin. 2019 Jan-Mar;5(1):2055217319827618. PubMed PMID: 30800417
• Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 Feb 12;92(7):e723-e732. PubMed PMID: 30635477
• Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G. International consensus on quality standards for brain health-focused care in multiple sclerosis. Mult Scler. 2019 Nov;25(13):1809-1818. PubMed PMID: 30381987
• Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H, Celius EG, Drulovic J, Flores J, Horáková D, Lebrun-Frénay C, Marrie RA, Overell J, Piehl F, Rasmussen PV, Sá MJ, Sîrbu CA, Skromne E, Torkildsen Ø, van Pesch V, Vollmer T, Zakaria M, Ziemssen T, Giovannoni G. International consensus on quality standards for brain health-focused care in multiple sclerosis. Mult Scler. 2018 Nov 1;:1352458518809326. [Epub ahead of print] PubMed PMID: 30381987
• Kuerten S, Jackson LJ, Kaye J, Vollmer TL. Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis. CNS Drugs. 2018 Nov;32(11):1039-1051. PubMed PMID: 30315499
• Vollmer B, Ontaneda D, Bandyopadhyay A, Cohn S, Nair K, Sillau S, Bermel RA, Corboy JR, Fox RJ, Vollmer T, Cohen JA, Alvarez E, Hersh CM. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurol Clin Pract. 2018 Aug;8(4):292-301. PubMed PMID: 30140580
• Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E. The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis. J Neurol Sci. 2018 Jul 15;390:89-93. PubMed PMID: 29801915
• Hebert JR, Corboy JR, Vollmer T, Forster JE, Schenkman M. Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS). Neurology. 2018 Feb 27;90(9):e797-e807. PubMed PMID: 29386274
• Vollmer B, Nair KV, Sillau SH, Corboy J, Vollmer T, Alvarez E. Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience. Mult Scler J Exp Transl Clin. 2017 Jul-Sep;3(3):2055217317725102. PubMed PMID: 28839949
• Foley JF, Nair KV, Vollmer T, Stephenson JJ, Niecko T, Agarwal SS, Watson C. Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis. Patient Prefer Adherence. 2017;11:1035-1048. PubMed PMID: 28670113
• Sørensen PS, Comi G, Vollmer TL, Montalban X, Kappos L, Dadon Y, Gorfine T, Margalit M, Sasson N, Rubinchick S, Knappertz V. Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials. Int J MS Care. 2017 Jan-Feb;19(1):16-24. PubMed PMID: 28243182
• Tyler KL, Vollmer TL. To PLEX or not to PLEX in natalizumab-associated PML. Neurology. 2017 Mar 21;88(12):1108-1109. PubMed PMID: 28228561
• Liu Y, Vollmer T, Havrdova E, Riester K, Lee A, Phillips G, Wang P, Sabatella G. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2017 Jan;11:18-24. PubMed PMID: 28104250
• Beseler C, Vollmer T, Graner M, Yu X. The complex relationship between oligoclonal bands, lymphocytes in the cerebrospinal fluid, and immunoglobulin G antibodies in multiple sclerosis: Indication of serum contribution. PLoS One. 2017;12(10):e0186842. PubMed PMID: 29059249
• Reichardt N, Vollmer M, Holtrop G, Farquharson FM, Wefers D, Bunzel M, Duncan SH, Drew JE, Williams LM, Milligan G, Preston T, Morrison D, Flint HJ, Louis P. Specific substrate-driven changes in human faecal microbiota composition contrast with functional redundancy in short-chain fatty acid production. ISME J. 2017 Dec 1. [Epub ahead of print] PubMed PMID: 29192904
• Otten C, Brilli M, Vollmer W, Viollier PH, Salje J. Peptidoglycan in Obligate Intracellular Bacteria. Mol Microbiol. 2017 Nov 27. [Epub ahead of print] PubMed PMID: 29178391
• Spina A, Lenglet A, Beversluis D, de Jong M, Vernier L, Spencer C, Andayi F, Kamau C, Vollmer S, Hogema B, Irwin A, Ngueremi Yary R, Mahamat Ali A, Moussa A, Alfani P, Sang S. A large outbreak of Hepatitis E virus genotype 1 infection in an urban setting in Chad likely linked to household level transmission factors, 2016-2017. PLoS One. 2017;12(11):e0188240. PubMed PMID: 29176816
• Mejza F, Gnatiuc L, Buist AS, Vollmer WM, Lamprecht B, Obaseki DO, Nastalek P, Nizankowska-Mogilnicka E, Burney PGJ. Prevalence and burden of chronic bronchitis symptoms: results from the BOLD study. Eur Respir J. 2017 Nov;50(5). PubMed PMID: 29167298
• Hofmann OT, Glowatzki H, Bürker C, Rangger GM, Bröker B, Niederhausen J, Hosokai T, Salzmann I, Blum RP, Rieger R, Vollmer A, Rajput P, Gerlach A, Müllen K, Schreiber F, Zojer E, Koch N, Duhm S. Orientation-Dependent Work-Function Modification Using Substituted Pyrene-Based Acceptors. J Phys Chem C Nanomater Interfaces. 2017 Nov 9;121(44):24657-24668. PubMed PMID: 29152034
• Kuhnt J, Vollmer S. Antenatal care services and its implications for vital and health outcomes of children: evidence from 193 surveys in 69 low-income and middle-income countries. BMJ Open. 2017 Nov 15;7(11):e017122. PubMed PMID: 29146636
• Vollmer J, Casares F, Iber D. Growth and size control during development. Open Biol. 2017 Nov;7(11). PubMed PMID: 29142108
• Robinson JC, Rostami N, Casement J, Vollmer W, Rickard AH, Jakubovics NS. ArcR Modulates Biofilm Formation in the Dental Plaque Colonizer Streptococcus gordonii. Mol Oral Microbiol. 2017 Nov 15. [Epub ahead of print] PubMed PMID: 29139600
• Vollmer K, Gfroerer S, Theilen TM, Bochennek K, Klingebiel T, Rolle U, Fiegel H. Radical Surgery Improves Survival in Patients with Stage 4 Neuroblastoma. World J Surg. 2017 Nov 10. [Epub ahead of print] PubMed PMID: 29127465
• Certner RH, Vollmer SV. Inhibiting Bacterial Quorum Sensing Arrests Coral Disease Development and Disease-Associated Microbes. Environ Microbiol. 2017 Nov 10. [Epub ahead of print] PubMed PMID: 29124861
• Mayer M, Takegami S, Neumeier M, Rink S, Jacobi von Wangelin A, Schulte S, Vollmer M, Griesbeck AG, Duerkop A, Baeumner AJ. Electrochemiluminescence Bioassays can outperform Fluorescence Assays using a New Water-soluble Luminol Derivative. Angew Chem Int Ed Engl. 2017 Nov 9. [Epub ahead of print] PubMed PMID: 29119667
• Vollmer R, Villagaray R, Cárdenas J, Castro M, Chávez O, Anglin NL, Ellis D. A large-scale viability assessment of the potato cryobank at the International Potato Center (CIP). In Vitro Cell Dev Biol Plant. 2017;53(4):309-317. PubMed PMID: 29104412
• Fuchs C, Wauschkuhn S, Scheer C, Vollmer M, Meissner K, Kuhn SO, Hahnenkamp K, Morelli A, Gründling M, Rehberg S. Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days. Br J Anaesth. 2017 Oct 1;119(4):616-625. PubMed PMID: 29121280
• Ozoh OB, Akanbi MO, Amadi CE, Vollmer W, Bruce N. The prevalence of and factors associated with tobacco smoking behavior among long-distance drivers in Lagos, Nigeria. Afr Health Sci. 2017 Sep;17(3):886-895. PubMed PMID: 29085417
• Vollmer S, Harttgen K, Kupka R, Subramanian SV. Levels and trends of childhood undernutrition by wealth and education according to a Composite Index of Anthropometric Failure: evidence from 146 Demographic and Health Surveys from 39 countries. BMJ Glob Health. 2017;2(2):e000206. PubMed PMID: 29081994
• Autoimmune Encephalitis: More Treatable if Treatable Early
• Phillips G, Guo S, Bender R, Havrdova E, Proskorovsky I, Vollmer T. Assessing the impact of multiple sclerosis disease activity and diclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Mult Scler and Rel Disord 6 (2016) 66-72
• Radue EW, Sprenger T, Vollmer T, Giovannoni G, Gold R, Havrdova E, Selmaj K, Stefoski D, You X, and Elkins J. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2016 Feb;23(2):412-5
• Sorensen PS, Comi G, Vollmer TL, Montalban X, Kappos L, Dadon Y, Gorfine T, Margalit M, Sasson N, Rubinchick S, Knappertz V. Laquinimod safety profile: pooled analyses from the ALLEGRO and BRAVO trials. [published online ahead of printing, March 7, 2016 doi:10.7224.2073.2015-024] Int J MS Care
• Calkwood J, Vollmer T, Fox RJ, Zhang R, Novas M, Sheikh SI, Viglietta V. Safety and Tolerability of Delayed Release Dimethyl Fumarate (DMF) when Administered in Combinaton w Interferon Beta or Glatiramer Acetate in Relapsing-Remitting MS. Int J of MS Care. 2016;18:138-146
• Vollmer TL, McCarthy M. Autoimmune Encephalitis: A More Treatable Tragedy if Diagnosed Early. Neurology 2016 May 3;86(18): 1655-6
• Ke X, Navaratnam P, Sasane R, Eisenberg Lawrence DF, Friedman HS, Tulsi BB, Vollmer T. Determinants of high cost in multiple sclerosis patients: a claims and chart review study. Current Medical Research and Opinion (2016). DOI: 10.1080/03007995.2016.1192529. http://dx.doi.org/10.1080/03007995.2016/1192529
• 167. Liu Y, Vollmer T, Havrdova E, Riester K, Lee A, Phillips G, Wang P, Sabatella G. Impact of daclizumab high-yield process versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler and Rel Dis. Jan. 2017;11: 18--24
• Bacci E, Phyllis G, Vollmer T, Guo S. Analysis of the Psychometric Properties of the Multiple Sclerosis Impact Scale-29 (MSIS-29) in Relapsing-Remitting Multiple Sclerosis using Classical and Modern Test Theory. Submitted to Multiple Sclerosis Journal March 28, 2016.
• Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani, M, Thalheim C, Traboulsee A, Giovannoni G, Vollmer T. Brain health: time matters in multiple sclerosis. Submitted to Multiple Sclerosis and Related Disorders. June, 2016
• Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A, Vollmer T. Time matters in multiple sclerosis-international consensus policy recommendations on diagnosis, management and treatment access. Poster and abstract accepted for presentation at the Annual meeting of the American Academy of Neurology, Vancouver, BC, Canada April, 2016
• Douglas J, Meier DP, Tomic D, Haring D, Vollmer T. MRI parameters as predictors of long-term disease outcome over 8 years in RRMS patients. Abstract and poster submitted for presentation to the European Academy of Neurology annual meeting, Copenhagen, Denmark, May, 2016
• Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A, Vollmer T. Time matters in multiple sclerosis-international consensus policy recommendations on diagnosis, management and treatment access. Poster and abstract accepted for presentation at the annual meeting of the Middle East and North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) Congress in Amman, Jordan, March, 2016
• Vollmer TL, Comi G, Kappos L, Montalban X, Cutter G, Steinerman J, Sasson N, Gorfine T, Knappertz V. Clinical efficacy of laquinimod 0.6 mg once daily in the treatment of worsening relapsing-remitting multiple sclerosis (baseline EDSS >3). P3.051 Poster and abstract accepted for presentation at the annual meeting of the American Academy of Neurology, April, 2016, Vancouver, Canada
• Alvarez E, Vollmer B, Sillau S, Nair K, Corboy J, Vollmer T, Honce J. The impact of very short transition times on switching from tysabri to gilenya on imaging and clinical effectiveness outcomes. P2.110. Poster and abstract accepted for presentation at the Annual Meeting of he American Academy of Neurology, Apri, 2016 Vancouver, BC, Canada
• Comi G, Vollmer TL, Kappos L, Montalban X, Sannon Nissim, Gorfine T, Knappertz V. Laquinimod Disability Progression Effects are Maintained with Increasingly Rigorous Confirmation Time Intervals. P3.069 Poster and abstract abstract accepted for presentation at the Annual Meeting of he American Academy of Neurology, April, 2016 Vancouver, BC, Canada
• Comi G, Vollmer TL, Lublin FD, Dadon Y, Gorfine T, Davis MD, Soelber Sorensen P, Knappertz V. Long-Term Follow-up of Laquinimod 0.6 mg in Patients with Relapsing-Remitting Multiple Sclerosis 2. P3.087 Poster and abstract abstract accepted for presentation at the Annual Meeting of he American Academy of Neurology, April, 2016 Vancouver, BC, Canada
• Ontaneda D, Vollmer B, Sillau S, Cohn S, Nair K. Bermel R, Vollmer T, Fox R, Corboy J. Cohen J. Hersh C, Alvarez E. Comparative Efficacy and Discontinuation of Fingolimod and Dimethyl Fumarate in Two Large Academic Medical Centers. P3.109 Poster and abstract abstract accepted for presentation at the Annual Meeting of the American Academy of Neurology, April, 2016 Vancouver, BC, Canada
• Costello K, Giovannon G, Butzkueven H, Dhib-Jalbut S, Hobart J. Kobelt G, Shift G, Sormani M, Thalheim C, Trabloulsee A, Vollmer T. Brain health: Time matters in multiple sclerosis—developmental process and objectives of international consensus policy recommendations. Accepted for poster presentation at the 2016 Consortium of Multiple Sclerosis Centers Annual Meeting, Maryland
• Carroll W, Giovannon G, Butzkueven H, Dhib-Jalbut S, Hobart J. Kobelt G, Shift G, Sormani M, Thalheim C, Trabloulsee A, Vollmer T. Brain health: Time matters in multiple sclerosis—developmental process and objectives of international consensus policy recommendations. Abstract accepted for presentation at the Australian & New Zealand Association of Neurologists (ANZAN) Annual Scientific Meeting May, 2016 Perth, Australia.
• Douglas J, Meier DP, Tomic D, Haring D, Vollmer T. MRI parameters as predictors of long-term disease outcome over 8 years in RRMS patients. Abstract and poster accepted for presentation at the Annual Meeting of the American Academy of Neurology, Vancouver, BC, Canada, April, 2016.
• Harlow D, Blauth K, Saul K, Selva S, Niedzielko T, Jackson L, Macklin W, Vollmer T. B Lymphocytes from MS Patients Induce CNS Pathology in Murine Brain Slice Model. Poster P5.321 presented at the Annual Meeting of the American Academy of Neurology, April, 2016, Vancouver, BC, Canada.
• Smith D, Bennett J, Miravalle A, Schreiner T, Corboy J, Vollmer T, Alvarez E, Blackburn J. Reclassification of a Large NMO Patient Cohort Using the 2015 NMO Spectrum Disorder Criteria. Poster P6.153 presented at the Annual Meeting of the American Academy of Neurology, April, 2016, Vancouver, BC, Canada.
• Honce J, Nair K, Hoyt B, Sillau S, Wedeman B, Engebretson E, Vollmer B, Johnson K, Tenenbaum N, Herrera V, Siconolfi L, Miravalle A, Bennett J, Corboy J, Vollmer T, Alvarez E. Comparison of Baseline Characteristics of Glatiramer Acetate Versus Fingolimod in Multiple Sclerosis Patients on Brain Volume, Cognition and Neuro-QOL Outcomes: Preliminary Analysis of a Longitudinal Observational Study. Poster P6.170 presented at the Annual Meeting of the American Academy of Neurology, April, 2016, Vancouver, BC, Canada.
• J Haas, T Vollmer, D Jeffery, DP Meier, B Stadler S Ritter, J Cohen, HP Hartung. Impact of continuous fingolimod therapy and switching to fingolimod on relapse severity in patients with relapsing-remitting multiple sclerosis. Abstract and poster presented at the 32ns Congress of the European Committee for Treatment and Research in MS (ECTRIMS), London, UK, September, 2016
• Vollmer BL, Nair K. Sillau SH, Corboy J, Vollmer TL, Alvarez E. Comparison of Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: Two Year Experience. Poster presented at the ECTRIMS annual meeting, London, September, 2016
• Vollmer BL, Chong KG, Campbell J. Corboy J. Vollmer T, Nair K. Evaluating the increase In the cost of Multiple Sclerosis drugs in the United States between 2010-2015: Market price vs Inflation based analysis. Poster presented at the ECTRIMS annual meeting, London, September, 2016
• McQueen, RB, Nair KV, Vollmer TL, Campbell JD. (2015): Incorporating real-world clinical practice in multiple sclerosis economic evaluations. Exp Rev of Pharmacoeconomics & Outcomes Research. http://dx.doi.org/10.14737167.2015.1081060
• McQueen RB, Livingston T, Vollmer TL, Corboy JR, Buckley B, Allen RR, Nair KV, Campbell JD. SPECIALTY Increased relapse activity for multiple sclerosis natalizumab users who become non-persistent: a retrospective study. Accepted by Journal of Managed Care & Specialty Pharmacy November 4, 2015
• Vollmer T, Signorovitch J, Huynh L, Galebach P, Kelley C, DiBernardo A, Sasane R. The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis. J Neurol Sci (2015) http://dx.doi.org/10.1016/j.jns2015.07.014
• Ying L, Vollmer T, Havrdova E, Riester K, Lee A, Phillips G, Elkins J. Treatment with Daclilzumab HYP Improved Disease-Specific Patient-Reported Outcomes Versus Interferon Beta-1a in Multiple Sclerosis in the Phase 3 DECIDE Trial. Poster P7.209 Presented at the 2015 Annual AAN Meeting, April 23, 2015 Washington, D.C.
• Comi G, Vollmer T, Montalban X, Ziemessen T, Boyko A, Vermersch P, Rachmilewitz, T, Sasson N, Gorfine T, Knappertz V Rocca M, Filippi M. Baseline characteristics of patients enrolled in CONCERTO – a study of 0.6 and 1.2 mg/day oral laquinimod for relapsing-remitting multiple sclerosis. Poster P7.216 Presented at the Annual AAN meeting April 23, 2015 Washington, D.C.
• Seibert J, Blackburn J, Vollmer B, Bennett J, Corboy J, Miravalle A, Schreiner T, Vollmer T, Alvarez E. Safety, Tolerability, and Efficacy of Rituximab in the Treatment of Multiple Sclerosis: 285 Patients Treated in a Single Center. Poster P3.262 Presented at the Annual AAN meeting April 21, 2015 Washington, D.C.
• Vollmer, B, Seibert J, Sillou S, Dowdle P, Corboy J, Vollmer T, Nair K, Alvarez E. Comparison of Fingolimod and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: One Year Experience. Poster P3.244 Presented at the Annual AAN meeting April 21, 2015 Washington, D.C
• McQueen R, Livingstone T, Vollmer T, Corboy J, Nair, K, Campbell J. Decreased Relapse Activity for those who Switch to Natalizumab from Alternative Disease Modifying Therapies: An Observational Study. Poster P3.272 Presented at the Annual AAN meeting April 21, 2015 Washington, D.C.
• Alvarez, E, Vollmer B, Blackburn J, Corboy J, Vollmer T Sillou S, Nair K, Seibert J. Effectiveness of Switching to Rituximab over Fingolimod or Dimethyl Fumarate after Natalizumab in Preventing Disease Activity in Multiple Sclerosis. Poster P3.288 Presented at the Annual AAN meeting April 21, 2015 Washington, D.C.
• Barkhof F, Giovannoni G, Hartung HP, Cree B, Uccelli A, Sormani MP, Krieger S, Uitehaag B, Vollmer T, Montalban X, Steinerman J, Sasson N, Gorfine T, Knappertz V . ARPEGGIO: A randomized, placebo-controlled study to evaluate oral laquinimod in patients with primary progressive multiple sclerosis (PPMS). Poster B7.210 Presented at the Annual AAN meeting April 23, 2015 Washington, D.C.
• Turner B, Vollmer T, Havrdova E, Lynch S, Wray S, Ford C, Wang P, Liu Y, Elkins J, Castro-Borrero W. Daclizumab HYP reduced psychological impact of multiple sclerosis versus intermuscular interferon Beta-1A in the DECIDE trial. Abstract/poster presented at the annual ECTRIMS meeting, October, 2015, Barcelona, Spain.
• Miravalle A, Honce J, Alvarez E, Nair K, Vollmer B, Sillau S, Corboy J, Vollmer T. Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? A longitudinal study using whole brain, neocortical and subcortical atrophy rates and patient reported outcomes (PROs). Interim analysis. Abstract and poster presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Barcelona, Spain, October, 2015
• Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A, Vollmer T. Time matters in multiple sclerosis—international consensus recommendations on diagnosis, management and access to treatment. Poster P1273 and abstract submitted for presentation at the 31st ECTRIMS, Barcelona, Spain, October, 2015
• Vollmer TL, Yuval D, Sidi Y, Ladkani D, Gorfine T, Sorensen PS. Switching from Interferon ?-1a I.M. to Laquinimod: Safety and Efficacy Results from the BRAVO Study Extension. Poster P054 and abstract presented at the 31st ECTRIMS meeting, Barcelona, Spain, October, 2015
• J.M. Honce , K.V. Nair , S. Sillau , A. Miravalle , B. Vollmer , T. Vollmer, J. Corboy, E. Alvarez. Evaluating the relationship between brain volume and patient reported outcomes using clinical and imaging parameters collected in the routine care of MS patients. Poster and abstract presented at the 31st ECTRIMS, Barcelona, Spain, October, 2015
• Vollmer T, Comi G, Cutter G, Giovannoni G, Steinerman J, Sasson N. Gorfine T, Knappertz V. Ambulation benefit with laquinimod in patients with worsening MS (EDSS over 3) is consistent with reduction in confirmed disability progression. Poster and abstract presented at the 31st ECTRIMS meeting, Barcelona, Spain, October, 2015
• Vollmer T, Signorovitch J, Huynh L, Galebach P, Kelley C, DiBernardo A, Sasane R. The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis. Poster and abstract presented at the 31st ECTRIMS meeting, Barcelona, Spain, October, 2015
• F. Zipp, T Vollmer, A Bar-Or, B Due, K. Thangavelu, TZ Fischer, K. Selmaj on behalf of the DreaMS Study Investigators. Relapse rates in patients with multiple sclerosis receiving ONO-4641, a sphingosine-1-phosphate receptor-1 and -5 agonist: interim results from an extension of the DreaMS study. Poster and abstract presented at the 31st ECTRIMS meeting, Barcelona, Spain, October, 2015
• A.T. Reder, D. Jeffery, D. Goodin, L Kappos, FD Lublin, E-W Radue, K. Rammohan, T. Vollmer, M.A. Agius, T. Stites, B. Li, L. Cappiello, P von Rosenstein, P.A. Calabresi. Long-term efficacy of fingolimod in patients with relapsing remitting multiple sclerosis: results from the phase 3 FREEDOMS II extension study. Poster and abstract presented at the 31st ECTRIMS meeting, Barcelona, Spain, October, 2015
• T. Vollmer, F Zipp, A Bar-Or, k. Thangavelu, T.Z. Fischer, K. Selmaj, on behalf of the DreaMS study investigators. Magnetic resonance imaging measures of efficacy in patients with multiple sclerosis receiving ONO-4641, a sphingosine-1-phosphate receptor-1 and -5 agonist: interim results from an extension of the DreaMS study. Poster and abstract presented at the 31st ECTRIMS meeting, Barcelona, Spain, October, 2015
• . Timothy L. Vollmer, Giancarlo Comi, Ludwig Kappos, Xavier Montalban, Gary Cutter, Joshua R. Steinerman, Nissim Sasson, Tali Gorfine, Volker Knappertz. Clinical efficacy of laquinimod 0.6mg once-daily in worsening relapsing-remitting multiple sclerosis defined by baseline EDSS over 3. Poster and abstract presented at the 31st ECTRIMS meeting, Barcelona, Spain, October, 2015
• Vollmer T, Comi G, Sorensen P, Sannon N, Gorfine T, Knappertz V. Temporal Pattern of Laboratory Changes with Laquinimod Treatment. Poster and abstract presented at the 31st ECTRIMS meeting, Barcelona, Spain, October, 2015
• A Bar-Or, T Vollmer, B Due, K. Thangavelu, J Johnson, K Selmaj on behalf of the DreaMS study investigators. Safety of ONO-4641 in patients with relapsing remitting multiple sclerosis: results from a six-month interim analysis of the DreaMS extension study. Poster and abstract presented at the 31st ECTRIMS meeting, Barcelona, Spain, October, 2015
• T Vollmer, EW Radue, P Bermersch, P von Rosenstiel, N Putzki, M Meinel, N Sfikas, M. Merschhemke and MS Freedman. Clinical and magnetic resonance imaging (MRI) disease activity after fingolimod discontinuation. Poster and abstract presented at the 31st ECTRIMS meeting, Barcelona, Spain, October, 2015
• K Selmaj, F Zipp, T Vollmer, A Bar-Or, B Due, TZ Fischer, K Thangevelu on behalf of the DreaMS study investigators. Effect of ONO-4641, a potent, oral, selective sphingosine-1-phosphate receptor-1 and -5 agonist, on MRI outcomes in patients with relapsing remitting multiple sclerosis: subgroup analyses from the phase 2 DreaMS study. Poster and abstract presented at the 31st ECTRIMS meeting, Barcelona, Spain, October, 2015
• Miravalle A, Smith D, Vollmer T, Corboy J, Bennett J. Schreiner T, Alvarez E. Berk J. Michas- Martin A, Cerdan-Trevino, M. Flynn B. Stein A, Valdez B, Jenkins, K. Rocky Mountain MS Center at University of Colorado Anschutz Medical Campus, Aurora, Co, USA. Improving bladder care for patients with multiple sclerosis. Poster and abstract presented at the 31st ECTRIMS meeting, Barcelona, Spain, October, 2015
• Miravalle, A, Smith, D, Honce, J. Alvarez E, Nair, KV, Sillau S, Vollmer B, Corboy J, Vollmer T. Rocky Mountain MS Center at University of Colorado Anschutz Medical Campus, Aurora, Co, USA Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing-Remitting Multiple Sclerosis (RRMS)? A Longitudinal Study Using Whole Brain, Neocortical and Subcortical Atrophy Rates and Patient Reported Outcomes (PROs). Interim Analysis. Poster and abstract presented at the 31st ECTRIMS meeting, Barcelona, Spain, October, 2015
• Smith D, Stein A, Miravalle A, Schreiner T, Corboy J, Vollmer T, Alvarez E. Central NervousSystem Neurosarcoidosis Experience at a Large Academic Center. Poster and abstract submitted for presentation at the Americas Association of Sarcoidosis and Other Granulomatous Disorders 9AASOG) conference, September 23—25, 2015 University of Colorado Anschutz Medical Campus, Aurora, Colorado
• Vollmer T, Huynh L, Kelley C, Galebach P, Signorovitch J, DiBernardo A, Sasane R. Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review and meta-analysis. Neurol. Sci. 2015/11/04. 1—15
• Ziemssen, T, Derfuss T, deStefano N, Giovannoni G, Palavra F, Tomic, D, Vollmer T, Schippling S. Optimizing treatment success in multiple sclerosis. Published online by J Neurol, Dec 24, 2015. ISSN 0340-5354. DOI 10.1007/s00415-015-7986. 1—13.
• Viglietta V, Sheikh S, Fox R, Calkwood J, Novas M, Zhang R, Vollmer T. Safety and Tolerability of Delayed Release Dimethyl Fumarate when Administered in Combinaton of Interferon Beta or Glatiramer Acetate in Relapsing-Remitting MS. Accepted for publication in International Journal of MS Care. September, 2015
• Radue EW, Sprenger T, Vollmer T, Giovannoni G, Gold R, Havrdova E, Selmaj K, Stefoski D, You X, and Elkins J. Daclizumab high-yeild process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis. Accepted for publication in J of Neurol December, 2015
• Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL on behalf of the BRAVO Study Group. A Randomized Placebo-Controlled Phase III Trial of Oral Laquinimod for Multiple Sclerosis. J Neurol published online February 28, 2014. DOI 10.1007/s00415-014-7264-4
• Eisenberg, DF, Navaratnum P, Ke X, Ramey N, Friedman H, Agashivala N, Sasane R, Vollmer T. Clinical characteristcs associated with high cost MS patients using claims and medical records data, stratified by cost. Abstract #2481 accepted for presentation at the Consortium of MS Centers/ACTRIMS Annual Meeting, Boston, MA September,2014
• Calkwood J, Viglietta V, Vollmer T, Zhang R, Novas M, Sheikh S, Fox RJ. Delayed-Release Dimethyl Fumerate As Add-on Therapy to Beta Interferon or Glatiramer Acetate in Relapsing-Remitting MS: Safety and Tolerability. Abstract submitted for presentation at the CMSC/ACTRIMS Annual Meeting, Boston, MA September, 2014
• Vollmer T, et. al. Abstract number 3189 Safety and tolerability of Delayed-Release Dimethyl Fumerate Administered as Add-On Therapy to Beta Interferons or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients. Accepted for platform presentation (S4.002) and INS Data Bliz (17-2.003)sessions at the annual American Academy of Neurology Annual Meeting, Philadelphia, PA 2014
• Vollmer T, et.al. Abstract number 1587 Impact of Natalizumab Treatment for Multiple Sclerosis on Patient-Reported Physical Functioning over 3 Years in US Clinical Practices abstract and poster accepted for presentation at the annual American Academy of Neurology Annual Meeting, Philadelphia, PA 2014
• Vollmer T, et. al. Abstract number 1515 Patient-Reported Psychological Functioning in Natalizumab-Treated Patients with Multiple Sclerosis in US Clinical Practice abstract and poster (P4.183) accepted for presentation at the annual American Academy of Neurology Annual Meeting, Philadelphia, PA 2014.
• Bar-Or A, Vollmer T, et. al Abstract number 1015 Effect of Ceralifimod (ONO-4641) a Sphingosine-1 Phosphate Receptor-1 and -5 Agonist, on Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis: Interim Results from the Extension of the DreaMS Study abstract and poster (Poster P3.161) accepted for presentation at the annual American Academy of Neurology Annual Meeting, Philadelphia, PA 2014
• Comi G, Vollmer T, et. al. Abstract number 3285 Mediation of the Effect of Laquinimod on Disability Progression in Relapsing-Remitting Multiple Sclerosis (RMMS) (Poster P3-195) accepted for presentation at the annual American Academy of Neurology Annual Meeting, Philadelphia, PA 2014
• McQueen RB, Vollmer T, et.al Abstract number 1316 Changes in Natalizumab Treatment Patterns and Association with Relapse Outcomes: A Retrospective Study abstract and poster (Poster P7-227) accepted for presentation at the annual American Academy of Neurology Annual Meeting, Philadelphia, PA 2014
• Jackson L, Vollmer T, et. al. Abstract number 999 B Lymphocytes Induce CNS Pathology Involving Reactive Astrogliosis and Oligodendrocyte loss in A Murine System and in Human Multiple Sclerosis. Accepted for platform presentation (S53.002) at the annual American Academy of Neurology Annual meeting, Philadelphia, PA 2014.
• Campbell J, McQueen RB, Box-Buckley, Briena, Livingston T, Vollmer T, Corboy J, Nair K.. Retrospective Real-World Four Year Study of Natalizumab Initiators: Persistence Versus Non-Persistence Impact on Relapses and Associated Costs. Poster and abstract accepted for presentation at the Academy of Managed Care Pharmacy 26th Annual Meeting & Expo in Tampa, FLA April, 2014
• McQueen RB, Nair K, Vollmer T, Campbell J. Aggressive natalizumab treatment for JC virus-negative relapsing-remitting multiple sclerosis? Cost-effectiveness of rist-line versus second-line natalizumamb treatment. Poster accepted for presentation at the 19th Annual ISPOR International meeting in Montrial, QC, Canada June 2, 2014
• Zhang C, Zhai H, Yan Y, Hao J, Li M, Jin W, Su N, Vollmer T, and Shi F. Glatiramer acetate ameliorates experimental autoimmune neuritis. Immunology and Cell Biology Feb 1, 2014; doi:10.1038/icb.2013.81
• Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL on behalf of the BRAVO Study Group. A Randomized Placebo-Controlled Phase III Trial of Oral Laquinimod for Multiple Sclerosis. J Neurol 261:4 773—83. April, 2014 DOI 10.1007/s00415-014-7264-4
• Jackson LJ, Selva S, Niedzielko T, Vollmer T (2014) B Cell Receptor Recognition of Glatiramer Acetate is Required for Efficacy through Antigen Presentationh and Cytokine Production. J Clin Cell Immunolog: 185.doi: 10.417212155-9899.1000185
• Calabresi PA, Radue E, Goodin D, Jeffery D, Rammohan K, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomized, placebo-controlled, phase 3 trial. The Lancet Neurology vol 13. 545-556. June, 2014
• Eisenberg, DF, Navaratnum P, Ke X, Ramey N, Friedman H, Agashivala N, Sasane R, Vollmer T. Clinical characteristcs associated with high cost MS patients using claims and medical records data, stratified by cost. Abstract #2481 presented at the Consortium of MS Centers/ACTRIMS Annual Meeting, Dallas, Texas, May, 2014
• Calkwood J, Viglietta V, Vollmer T, Zhang R, Novas M, Sheikh S, Fox RJ. Delayed-Release Dimethyl Fumerate As Add-on Therapy to Beta Interferon or Glatiramer Acetate in Relapsing-Remitting MS: Safety and Tolerability. Abstract presented at the CMSC/ACTRIMS Annual Meeting, Dallas, Texas, May, 2014
• 131. Viglietta V, Vollmer T, Zhang R, Novas M, Sheikh S, Fox R. Abstract number 3189 Safety and tolerability of Delayed-Release Dimethyl Fumerate Administered as Add-On Therapy to Beta Interferons or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients. Accepted for platform presentation (S4.002) and INS Data Bliz (17-2.003)sessions at the annual American Academy of Neurology Annual Meeting, Philadelphia, PA 2014
• Vollmer T, Foley J, Nair K, Sstephenson J, Niecko T, Agarwal S, Watson C. Abstract number 1587 and Poster P7.210 Impact of Natalizumab Treatment for Multiple Sclerosis on Patient-Reported Physical Functioning over 3 Years in US Clinical Practice presented at the annual American Academy of Neurology Annual Meeting, Philadelphia, PA 2014.
• Foley J. Nair K, Stephenson J, Vollmer T, Niecko T, Agarwal S, Watson C. Abstract number 1515 Patient-Reported Psychological Functioning in Natalizumab-Treated Patients with Multiple Sclerosis in US Clinical Practice abstract and poster (P4.183) presented at the annual American Academy of Neurology Annual Meeting, Philadelphia, PA 2014.
• Bar-Or A, Vollmer T, et.al Abstract number 1015 Effect of Ceralifimod (ONO-4641) a Sphingosine-1 Phosphate Receptor-1 and -5 Agonist, on Magnetic Resonance Imaging Outcomes in Patients with Multiple Sclerosis: Interim Results from the Extension of the DreaMS Study abstract and poster (Poster P3.161) presented at the annual American Academy of Neurology Annual Meeting, Philadelphia, PA 2014.
• Comi G, Vollmer T, et.al. Abstract number 3285 Mediation of the Effect of Laquinimod on Disability Progression in Relapsing-Remitting Multiple Sclerosis (RMMS) (Poster P3-195) presented at the annual American Academy of Neurology Annual Meeting, Philadelphia, PA 2014.
• McQueen RB, Vollmer T, et.al Abstract number 1316 Changes in Natalizumab Treatment Patterns and Association with Relapse Outcomes: A Retrospective Stud. Abstract and poster P7-227 presented at the annual American Academy of Neurology Annual Meeting, Philadelphia, PA 2014.
• McQueen RB, Box-Buckley B, Livingston T, Vollmer T, Corboy J, Nair K, Campbell J. Changes in natalizumab Real-World Treatment Patterns and Association with Relapse Outcomes: A Retrospective Study. Abstract and poster presented at the Academy of Managed Care Pharmacy Annual Meeting & Expo in Tampa, FL April 1-4, 2014
• Campbell J, McQueen RB, Cox-Buckley B, Livingston T, Vollmer T, Corboy J, Nair K. Retrospective Real-World four-year Study of Natalizumab Initiators: Persistence Versus Non-Persistence Impact on Relapses and Associated Costs. Abstract and poster presented at the CMSC Annual meeting in Dallas, Texas May, 2014.
• McQueen RB, Nair K, Vollmer T, Campbell J. Aggressive natalizumab treatment for JC virus-negative relapsing-remitting multiple sclerosis? Cost-effectiveness of risk-line versus second-line natalizumamb treatment. Poster presented at the 19th Annual ISPOR International meeting in Montreal, QC, Canada June 2, 2014
• Vollmer T, et. al. Clinical Characteristics Associated with High cost MS Patients Using Claims and Medical Records Data, Stratified by Cost. Abstract and Poster presented at the CMSC Annual meeting in Dallas, TX , May, 2014.
• Nayak R, Vollmer T, Bomprezzi R, Jacolik R. (P4.128) Recirculating Phagocytes are a Novel Source of Biomarkers for Brain Injury, Poster and abstract presented at the annual meeting of the American Academy of Neurology, Philadelphia, PA April, 2014
• Yu X, Dennis K, Pointon T, Vollmer T. (P4.135) Reduced level of Sialylated IgG Antibody in the CSF of Patients with Multiple Sclerosis. Poster and abstracted presented at the annual meeting of the American Academy of Neurology, Philadelphia, PA April, 2014
• Comi G, Vollmer T, Kappos L, Montalban X, Sasson N, Gorfine T, Knapperz V. (P070) Laquinimod Disability Progression Effects are Maintained with Increasingly Rigorous Confirmation Time Intervals.. Poster presentation at the 2014 Joint ACTRIMS-ECTRIMS meeting in Boston, MA September, 2014
• Vollmer T, Dadon Y, Sisi Y, Ladkani D, Gorfine T, Sorensen P. (P054) Switching From Interferon B-1a IM to Laquinimod: Safety and Efficacy Results from the BRAVO Study Extension. Poster presentation at the 2014 Joint ACTRIMS-ECTRIMS meeting in Boston, MA Sept., 2014
• Vollmer T, Comi G, Kappos L, Montalban X, Cutter G, Steinerman J, Sasson N, Gorfine T, Knappertz V. (P062) Clinical Efficacy of Laquinimod 0.6 mg Once-Daily in Worsening Relapsing-Remitting Multiple Sclerosis (Defined by baseline EDSS Over 3). Poster presentation at the 2014 Joint ACTRIMS-ECTRIMS meeting in Boston, MA Sept., 2014
• Vollmer T, Comi G, Sorensen P, Sasson N, Gorfine T, Knappertz V. (P071) Temporal Pattern of Laboratory Changes with Laquinimod Treatment. Poster presentation at the 2014 Joint ACTRIMS-ECTRIMS meeting in Boston, MA Sept., 2014
• Sormani M, Vollmer T, Comi G, Sidi Y, Steinerman J, Gorfine T, Knappertz V. (P069) Laquinimod Effect on Confirmed Disability Progression: Minimal Mediation by Relapse or T2 Lesions Reduction. Poster presentation at the 2014 Joint ACTRIMS-ECTRIMS meeting in Boston, MA Sept., 2014
• Comi, G, Vollmer T, Kappos D, Montalban X, Gorfine T, Sasson N, Knappertz V. (P061) Consistent Effect of Laquinimod on Relapse-Related and Disability Progression-Related Endpoints. Poster presentation at the 2014 Joint ACTRIMS-ECTRIMS meeting in Boston, MA Sept., 2014
• Nakamura K, Vollmer T, Gorfine T, Knappertz V, Arnold D. (P041) Effect of Laquinimod on Gray Matter and White Matter Atrophy in Relapsing-Remitting Multiple Sclerosis: Analysis of the BRAVO Phase III Trial. Poster presentation at the 2014 Joint ACTRIMS-ECTRIMS meeting in Boston, MA Sept., 2014
• McQueen RB, Livingston T, Vollmer TL, Corboy JR, Buckley B, Allen RR, Nair KV, Campbell JD. SPECIALTY Increased relapse activity for multiple sclerosis natalizumab users who become non-persistent: a retrospective study. Accepted by Journal of Managed Care & Specialty Pharmacy November 4, 2014
• Vollmer T, Jeffrey D, Goodin D, Kappos L, Lublin F, Radue EW, Rammohan K, Reder A, Agius M, Stites T, Li B, Cappiello L, von Rosenstiel P, Calabresi P. Long-term Safety of Fingolimod in Patients with Relapsing-remitting Multiple Sclerosis: Results from Phase 3 FREEDOMS II Extension Study. Abstract (#1030) and poster presented at the AAN Annual meeting in San Diego, CA March, 2013
• Vollmer TL, Arnold D, Cohen J, Coles A, Confavreau C, Fox E, Hartung H, Havrdova E, Selmaj K, Weiner H, Twyman C, Miller T, Lake S, Margolin D, Panzara M, Compston A. Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis in Patients Who had Disease Activity on Prior therapy. Abstract accepted for presentation to the American Academy of Neurology annual meeting in San Diego, CA March, 2013
• Vollmer TL, Havrdova E, Krzysztof S, Elkins J, Hass S, Guo S, Proskorovsky I. Daclizumab High-Yield Process Treatment Reduced the Impact of Multiple Sclerosis Relapse on Health-Related Quality of Life (Results of the SELECT trial). Abstract and poster presented at the American Academy of Neurology Annual meeting in San Diego, CA, March, 2013
• Vollmer TL, Chen D, Nance P, Ellenbogen A, Flitman S, Garrison J, Huddleston J, Huffman C, Mayadev A, Patel N, Patton J, Thrower B, Lissin D. An ongoing Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis. Abstract and poster presented at the American Academy of Neurology annual meeting in San Diego, CA, March, 2013
• Campbell JD, Ghushchyan V, McQueen RB, Cahoon-Metzger S, Livingston T, Vollmer T, Corboy J. Miravalle A, Schreiner T, Nair, K. Direct Costs, Indirect Costs, and Quality of Life Burden of Multiple Sclerosis: National U.S. Estimates. Abstract and poster presented at the American Academy of Neurology annual meeting in San Diego, CA, March, 2013.
• Bar-Or A, Zipp F, Krysztof S, Due B, Vollmer TL, The Effect of the Sphingosine 1-Phosphate Receptor Agonist ONO-461 On Circulating Lymphocytes in Patients with Relapsing Remitting Multiple Sclerosis: Results from the Phase 1 DreaMS Trial. Abstract and poster presented at the American Academy of Neurology annual meeting, San Diego, CA March, 2013
• Goodin D, Jeffery D, Kappos L, Lublin F, Radu EW, Rammohan K, Reder A,Vollmer TL, Agius M, Stites T, Li B, Cappiello L, von Rosenstiel P, Calabresi P. Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis. Abstract and Poster presented at the American Academy of Neurology annual meeting, San Diego, CA March, 2013
• Selmaj K, Zipp F, Vollmer T, Bar-Or A, Due B, VanBeek, J, Thangavelu K. An exploratory analysis of magnetic resonance imaging outcomes in the DreaMS trial: a double-blilnd, placebo-controlled, Phase 2, 26-week trial of a selective sphingosine 1-phosphate receptor agonist ONO-4641 in patients with relapsing-remitting multiple sclerosis. Poster presented at the American Academy of Neurology annual meeting, San Diego, CA March, 2013
• Vollmer TL, Stalla-Bourdillo A, Robinson M. Teriflunomide in Routine Clinical Practice: Design of the Teri-PRO Study. Abstract presented to the 27th Annual meeting of the CMSC and the 5th Cooperative Meeting of the CMSC-ACTRIMS, Orlando, FL May, 2013
• Vollmer T, Radue E-W, Vermersch P, von Rosensteil P, Putzki N, Meinel M, Sfikas N, Merschhemke M, Freedman M. Clinical and magnetic resonance imaging (MRI) disease activity after fingolimod discontinuation. Abstract presented at ECTRIMS annual meeting, October, 2013 Copenhagen, Denmark
• Bar-Or A, Zipp F, Vollmer T, Due B, Thangavelu K, Johnson J, Selmaj K on behalf of the DreaMS study investigators. Safety of ONO-461 in patients with relapsing-remitting multiple sclerosis: results from the 6-month interim analysis of the DreaMS extension study. Abstract number 1015 presented at ECTRIMS annual meeting October, 2013 Copenhagen, Denmark
• Selmaj K, Zipp F, Vollmer T, Bar-Or A, Due B, Fisher TZ, Thangavelu K on behalf of the DreaMS study investigators. Effect of ONO-4641 a potent, oral, elective sphingosine-1-phosphate receptor-1 and -5 agonist, on MRI outcomes in patients with relapsing-remitting multiple sclerosis: subgroup analysis from the Phase II DreaMS study. Abstract number 941 presented at ECTRIMS annual meeting, October, 2013 in Copenhagen, Denmark
• Vollmer T, Zipp F, Bar-Or A, Due B, Thangavelu K, Fisher TZ, Selmaj K on behalf of the DreaMS study investigators. Magnetic resonance imaging measures of efficacy in patients with multiple sclerosis receiving ONO-4641, a sphingosine-1-phosphate receptor-1 and -5 agonist: interim results from an extension of the DreaMS study. Abstract number 954 presented at ECTRIMS annual meeting October, 2013 Copenhagen, Denmark
• Reder AT, Jeffery D, Goodin D, Kappos L, Lublin FD, Radue EW, Rammohan K, Vollmer T, Agius MA, Stites T, Li B, Cappiello L. von Rosenstein P, Calabresi PA. Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis: Results from the phase 3 FREEDOMS II extension study. Abstract presented at ECTRIMS annual meeting October, 2013, Copenhagen, Denmark
• Vollmer T, Sorensen P.S., Selmaj K., Zipp F, Havrdova E, Cohen J, Sidi Y, Gordine T, Arnold D for the BRAVO Study Group. Results of switching to laquinimod in the open-label extension phase of the BRAVO Study. Abstract No. 566 and poster presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and the 18th Annual Conference of Rehabilitation in MS (RIMS) Copenhagen, Denmark October, 201
• Somani MP, Cutter G, Comi G, Vollmer T, Sorensen PS, Lakani D, Sasson N, Knappertz V. Evaluating the relationship between laquinimod’s effects on relapse and disability progression. Abstract No. 585 and poster presented at ECTRIMS annual meeting October, 2013, Copenhagen, Denmark
• Sorensen PS, Cutter G, Vollmer T, Comi G, Ladkani D, Sasson N. Knappertz V. The risk of disability progression is associated with multiple sclerosis functional composite (MSFC) scores in the laquinimod phase 3 trials. Abstract No. 608 and poster presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and the 18th Annual Conference of Rehabilitation in MS (RIMS) Copenhagen, Denmark October, 2013.
• Vollmer T, Montalban X, Comi G, Ziemssen T, Boyko A, Vermersch P, Sasson N, Gorfine T, Knappertz V, Filippi M. Multicentre, randomized, placebo-controlled study to evaluate the efficacy and tolerability fo two doses of oral laquinimod (0.6 mg/day and 1.2 mg/day) for the treatment of patients with relapsing remitting multiple sclerosis. Abstract No. 576 and poster presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and the 18th Annual Conference of Rehabilitation in MS (RIMS) Copenhagen, Denmark October, 2013
• Comi G, Vollmer T, Cutter G, Sasson N, Ladkani D, Gorfine T. Disease progression in relapse-free patients treated with laquinimod. Abstract No. 1044 and poster presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and the 18th Annual Conference of Rehabilitation in MS (RIMS) Copenhagen, Denmark October, 2013.
• Cutter G, Comi G, Vollmer T, Ladkani D, Sasson N. Knappertz V. Baysian analysis of laquinimod’s effect on relapses and disability. Abstract No. 609 and poster presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), and the 18th Annual Conference of Rehabilitation in MS (RIMS) Copenhagen, Denmark October, 2013.
• Schwartz CE, Snook E, Quaranto B, Benedict RH, Vollmer T. Cognitive reserve and patient-reported outcomes in multiple sclerosis. Multiple Sclerosis Jan. 2013 19:1 87-105
• Schwartz, CE, Quaranto BR, Healy BC, Benedict RHB, Vollmer T. Altruism and health outcomes in multiple sclerosis: The effect of cognitive reserve. The Journal of Positive Psychology: Dedicated to furthering Research and promoting good practice, March, 2013 8:2, 144-152
• Vollmer T, Jeffrey D, Goodin D, Kappos L, Lublin F, Radue EW, Rammohan K, Reder A, Agius M, Stites T, Li B, Cappiello L, von Rosenstiel P, Calabresi P. Long-term Safety of Fingolimod in Patients with Relapsing-remitting Multiple Sclerosis: Results from Phase 3 FREEDOMS II Extension Study. Abstract (#1030) and poster presented at the AAN Annual meeting in San Diego, CA March, 2013
• Vollmer TL, Arnold D, Cohen J, Coles A, Confavreau C, Fox E, Hartung H, Havrdova E, Selmaj K, Weiner H, Twyman C, Miller T, Lake S, Margolin D, Panzara M, Compston A. Alemtuzumab Reduces MS Disease Activity in Active Relapsing-Remitting Multiple Sclerosis in Patients Who had Disease Activity on Prior therapy. Abstract accepted for presentation to the American Academy of Neurology annual meeting in San Diego, CA March, 2013
• Vollmer TL, Havrdova E, Krzysztof S, Elkins J, Hass S, Guo S, Proskorovsky I. Daclizumab High-Yield Process Treatment Reduced the Impact of Multiple Sclerosis Relapse on Health-Related Quality of Life (Results of the SELECT trial). Abstract and poster presented at the American Academy of Neurology Annual meeting in San Diego, CA, March, 2013
• Vollmer TL, Chen D, Nance P, Ellenbogen A, Flitman S, Garrison J, Huddleston J, Huffman C, Mayadev A, Patel N, Patton J, Thrower B, Lissin D. An ongoing Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis. Abstract and poster presented at the American Academy of Neurology annual meeting in San Diego, CA, March, 2013
• Campbell JD, Ghushchyan V, McQueen RB, Cahoon-Metzger S, Livingston T, Vollmer T, Corboy J. Miravalle A, Schreiner T, Nair, K. Direct Costs, Indirect Costs, and Quality of Life Burden of Multiple Sclerosis: National U.S. Estimates. Abstract and poster presented at the American Academy of Neurology annual meeting in San Diego, CA, March, 2013
• Bar-Or A, Zipp F, Krysztof S, Due B, Vollmer TL, The Effect of the Sphingosine 1-Phosphate Receptor Agonist ONO-461 On Circulating Lymphocytes in Patients with Relapsing Remitting Multiple Sclerosis: Results from the Phase 1 DreaMS Trial. Abstract and poster presented at the American Academy of Neurology annual meeting, San Diego, CA March, 2013
• Goodin D, Jeffery D, Kappos L, Lublin F, Radu EW, Rammohan K, Reder A,Vollmer TL, Agius M, Stites T, Li B, Cappiello L, von Rosenstiel P, Calabresi P. Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis. Abstract and Poster presented at the American Academy of Neurology annual meeting, San Diego, CA March, 2013
• Selmaj K, Zipp F, Vollmer T, Bar-Or A, Due B, VanBeek, J, Thangavelu K. An exploratory analysis of magnetic resonance imaging outcomes in the DreaMS trial: a double-blilnd, placebo-controlled, Phase 2, 26-week trial of a selective sphingosine 1-phosphate receptor agonist ONO-4641 in patients with relapsing-remitting multiple sclerosis. Poster presented at the American Academy of Neurology annual meeting, San Diego, CA March, 2013
• Vollmer TL, Stalla-Bourdillo A, Robinson M. Teriflunomide in Routine Clinical Practice: Design of the Teri-PRO Study. Abstract presented to the 27th Annual meeting of the CMSC and the 5th Cooperative Meeting of the CMSC-ACTRIMS, Orlando, FL May, 2013
• Schwartz CE, Quaranto BR, Healy BC, Benedict RHB, Vollmer T. Altruism and health outcomes in multiple sclerosis: The effect of cognitive reserve. The Journal of Positive Psychology: Dedicated to furthering Research and promoting good practice, March, 2013 8:2, 144-152
• Schwartz CE, Snook E, Quaranto B, Benedict RH, Vollmer T. Cognitive reserve and patient-reported outcomes in multiple sclerosis. Multiple Sclerosis Jan. 2013 19:1 87-105
• Campbell J, McQueen R, Miravalle A, Corboy J,Vollmer T, Nair, K. Comparative effectiveness of early natalizumab treatment in JC virus negative relapsing-remitting multiple sclerosis. American Journal of Managed Care. 2013;19(4):278-285
• Salter AR, Tyry T, Vollmer T, Cutter GR, Marrie RA. “Seeing” in NARCOMS: a look at vision-related quality of life in the NARCOMS registry. Multiple Sclerosis June 2013 19:7 953-60
• Schwart CE, Quaranto BS, Healy BC, Benedict RH, Vollmer TL. Cognitive reserve and symptom experience in multiple sclerosis: A buffer to disability progression over time? Archives of Physical Medicine and Rehabilitation Oct. 2013 94:10 1971-1981 e1
• Schwartz, CE, Quaranto BR, Rapkin BD, Healy BC, Vollmer T and Sprangers MAG. Fluctuations in appraisal over time in the context of stable versus non-stable health. Quality of Life Research DOI 10.1007/s1113601304710 published online July 13, 2013
• Brueck W, Gold R, Lund B, Oreja-Guevara C, Prat A, Oreja-Guevara O, Prat A, Spencer CM, Steinman L, Tintore M, Vollmer T, Weber MS, Weiner LP, Ziemssen T, Zamvil S. Therapeutic Decisions in Multiple Sclerosis: Moving Beyond Efficacy. JAMA Neurology, Aug 5, 2013 DOI 10.1001/jamaneurol.2013.3510
• Foley, FW, Zemon V, Campagnolo D, Marrie, RA, Cutter, G, Tyry T, Beier M, Farrell E, Vollmer T, Schairer L. The Multiple sclerosis intimacy and sexuality Questionnaire—re-validation and development of a 15-item version with a large US sample. Multiple Sclerosis Aug 2013 19:9 1197-203
• Vollmer, TL, Robinson MJ, Risser RC, Malcolm SK. A Randomized, Double-blind, Placebo-controlled Trial of Duloxetine for the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis. Pain Practice, Oct 24, 2013 DOI 10.1111/papr.12127
• Campbell JD, Ghushchyan V, McQueen RB, Cahoon-Metzger S, Livingston T, Vollmer T, Corboy J, Miravalle A, Schreiner T, Porter V, Nair K. Burden of Multiple Sclerosis on Direct, Indirect Costs and Quality of Life: National US Estimates. Multiple Sclerosis and Related Disorders (2013) http://dx.doi.org/10.1016/j.msard.2013.09.004
• Brueck, W, Vollmer T et. al Oral laquinimod for MS-bringing the brain into focus. Accepted for publication in Nature Reviews Neurology November 26, 2013; doi:10.1038/nmeurol.2013.234
• Zhang C, Zhai H, Yan Y, Hao J, Li M, Jin W, Su N, Vollmer T, and Shi F. Glatiramer acetate ameliorates experimental autoimmune neuritis. Immunology and Cell Biology Nov 26, 2013; doi:10.1038/icb.2013.81
• Vollmer TL, Stalla-Bourdillon A, Robinson M. Teriflunomide in Routine Clinical Practice: Design of . the Teri-PRO Study. [CMSC abstract CG01]. Int J MS Care. 2013;15(suppl 3):37
• Campbell J, McQueen RB, Cox-Buckley B, Livingston T, Vollmer T, Corboy J, Nair K.. Retrospective Real-World Four0Year Study of Natalizumab Initiators: Persistence Versus Non-Persistence Impact on Relapses and Associated Costs. Accepted for publication in The Journal of Managed Care Pharmacy, April, 2014
• Comi G, Vollmer T, Sorensen PS, Arnold D, Jeffery D, Montalban X, Kappos L, Boyko A, Selmaj K, Zipp F, Havrdova E, Cohen J, Sasson N, Sidi Y, Gilgun-Sherki Y, Knappertz V. Efficacy of Laquinimod in Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Results of the Phase III ALLEGRO and BRAVO Trials. Submitted to the Multiple Sclerosis Journal February, 2014
• Schowinsky J, Corboy J, Vollmer T, Keinschmidt-Demaster BK. Natalizumab-associated T cell complications: first case of peripheral T cell lymphoma and second case of PML-IRIS and clonal T cell production. Poster and abstract presented at the 101st Annual meeting of the United States and Canadian Academy of Pathology in Vancouver, British Columbia, Canada March 17-23, 2012
• Vollmer T, Comi G, Sorensen PS, Arnold D, Filippi M, Statinova O, Kobys t, Becker E, Jeffrey D, Montalban X, Kappos L, Boyko A, Selmaj K, Zipp F, Havrdova E, Cohen J. Clinical efficacy of laquinimod for the treatment of multiple Sclerosis; pooled analyses from the ALLEGRO and BRAVO Phase III trials. Poster and abstract presented at the 64th Annual American Academy of Neurology meeting, New Orleans, LA April 24, 2012
• Comi G, Vollmer T, Sorensen PS, Arnold D, Filippi M, Statinov O, Kobys T, Becker E, Jeffrey D, Montalban X, Kappos L, Boyko A, Selmaj K, Zipp F, Havrdova E, Cohen J. Pooled analyses from the ALLEGRO and BRAVO trials on the safety and tolerability of laquinimod as a multiple sclerosis treatment. Abstract and poster presented at the 64th Annual American Academy of Neurology Meeting, New Orleans, LA April 25, 2012.
• Campbell J, McQueen RB, Corboy J, Vollmer T, Nair K. New versus old: long-term comparative effectiveness research projections for disease modifying therapies in relapsing-remitting multiple sclerosis. Abstract and poster presented at 64th Annual American Academy of Neurology meeting, New Orleans, LA April 26, 2012
• Vollmer TL, Selmaj KW. Bar-Or A, Zipp F. A double-blind, placebo-controlled, phase2, 26-week DreaMS trial of a selective S1P receptor agnonists ONO 4641 in patients with relapsing-remitting multiple sclerosis. Abstract and poster presentation at the 64th Annual American Academy of Neurology meeting, New Orleans, LA, April 25, 2012
• Calabresi PA, Radue EW, Goodin D, Jeffrey D, Rammohan K, Reder AT, Vollmer T, Agius MA,Kappos L, Li G, Cappiello L, Malhotra M, von Rosenstiel P, Lublin FD. Efficacy and safety of fingolimod in patients with relapsing remitting multiple sclerosis (RRMS): Results from an additional 24-month double-blind, placebo-controlled study (FREEDOMS II Study)” Abstract presented at platform presentation at the 64th Annual American Academy of Neurology meeting, New Orleans, LA. April, 2012
• Schreiner T, Corboy J, Bennett J, Miravalle A, Vollmer T. Comparing rituximab induction followed by glatiramer acetate to glatiramer acetate alone in patients with MS. Poster and abstract presented at the annual Consortium of MS Centers meeting in San Diego, CA May, 2012
• Vollmer T, Goodin D, Jeffrey D, Kappos L, Radue E-W, Reder AT, Agius MA, Cappiello L, Stiles T, Li B, Mahotra M, von Rosensteil P, Calabresi PA. Effect of fingolimod on severe relapses, healthcare utilization and relapse recovery in patients with relapsing-remitting multiple sclerosis: Results from the phase 3 FREEDOMS II study. Abstract and poster presented at the 28th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS), October 10-13, 2012, Lyon, France
• Zipp F, Vollmer TL, Selmaj KW, Bar-Or A on behalf of the DreaMS Study Group. Efficacy and safety of the S1P receptor agonist ONO-4641 in patients with rlapsing-remitting multiple sclerosis: results of a 26-week, double-blind, placebo-controlled, phase II trial (DreaMS). Abstract and poster presented at the 28th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS), October 10-13, 2012, Lyon, France
• Calabresi PA, Goodin D, Jeffrey D, Kappos L, Lublin FD, Rammohan K, Reder AT, Vollmer T, Agius MA, Cappiello L, Stites T, Li BB, Malhotra M, von Rosensteil P, Radue E.-W. Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing-remitting multiple sclerosis. Abstract presented at the 28th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS), October 10-13, 2012, Lyon, France
• Quaranto BR, Healy BC, Vollmer TL, Benedict RHB, Schwartz CE. Cognitive reserve and symptom experience in multiple scerosis: a buffer to disability progression over time? Abstract presented at the 28th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS), October 10-13, 2012, Lyon, France
• Radue E.-W, Goodin D, Jeffrey D, Kappos L, Lublin FD, Rammahan K, Reder AT, Vollmer T, Agius MA, Cappiello L, Stites T, Li BB, Malhotra M, von Rosenstiel P, Calabresi PA. Fingolimod reduces magnetic resonance imaging inflammatory lesion activity versus placebo in patients with relapsing-remitting multiple sclerosis: results from the phase 3 FREDDOMS study. Abstract presented at the 28th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS), October 10-13, 2012, Lyon, France
• Moberly J, Vollmer T et. al Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients. Accepted for publication in J of Neuroimmunology, in press March, 2012
• Schwartz CE, Bode RK, Vollmer T. The symptom inventory disability-specific short-forms for multiple sclerosis: Reliability and factor structure. Archivies of Physical Medicine and Rehabilitation, 2012 (in press)
• Schowinksi J, Corboy J, Vollmer T, Kleinschmidt-DeMasters BK. Natalizumab-associated complication? First case of peripheral T cell lymphoma. 2012 Acta Neuropathol 2012 123:5 751-752 10.1007/s00401-012-0967-7
• Waubant E, Pelletier D, Mass M, Cohen J, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stuve O, Schwid S, Goodman A, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi P, Miller A, Mokhtarani M, Ikle D, Murphy S, Kopetski H, Ding L, Rosenberg E, ITN020AI Study Management team Spencer C, Zamvil SS. Randomized controlled study of Atorvastatin in clinically isolated syndrome: the STAyCIS study. 2012. Neurology. 78:15 1171-8 DOI:10.1212/WNL.0b013e31824f7dd
• Moberly JB, Ford DM, Zahir H, Chen S, Mochizuki T, Truitt KE, Vollmer T. Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients. Published online ahead of printing in J. Neuroimmunology (2012), doi:10.1016/j.jneuroim.2012.03.007.
• Schwartz CE, Benedit R, Snook E, Vollmer T, Quaranto B. Cognitive reserve and patient reported outcomes in multiple sclerosis. Publiched on line in Multiple Sclerosis Journal, 30 April 2012, DO:10.1177/1352458512444914
• Vollmer TL, Benedict R, Bennett S, Motl RW, White AT, Bombardier CH, Hebert JR. Exercise as prescriptive therapy in multiple sclerosis. International Journal of MS Care 2012 14:S3 2-14.
• Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab. J Neuropathol Exp Neurol 2012 71:7 July 2012 604-617
• Schwartz CE, Bode RK, Quaranto BR, Vollmer TL. The symptom inventory disability-specific short forms for multiple sclerosis: Construct validity and responsiveness, and interpretation. Archives of Physical Medicine and Rehabilitation, Sept. 2012 93:1617-1628.e1
• Schwartz CE, Bode RK, Vollmer T. The symptom inventory disability-specific short forms for multiple sclerosis: Reliability and factor structure. Archives of Physical Medicine and Rehabilitation Sept. 2012 93: 1629-1636.e2
• Volmer T, Comi G, Sorensen PS, Arnold D, Filippi M, Statinova O, Kobys t, Becker E, Jeffrey D, Montalban X, Kappos L, Boyko A, Selmaj K, Zipp F, Havrdova E, Cohen J. Clinical efficacy of laquinimod for the treatment of multiple Sclerosis; pooled analyses from the ALLEGRO and BRAVO Phase III trials. Poster and abstract presented at the 64th Annual American Academy of Neurology meeting, New Orleans, LA April 24, 2012
• Comi G, Vollmer T, Sorensen PS, Arnold D, Filippi M, Statinov O, Kobys T, Becker E, Jeffrey D, Montalban X, Kappos L, Boyko A, Selmaj K, Zipp F, Havrdova E, Cohen J. Pooled analyses from the ALLEGRO and BRAVO trials on the safety and tolerability of laquinimod as a multiple sclerosis treatment. Abstract and poster presented at the 64th Annual American Academy of Neurology Meeting, New Orleas, LA April 25, 2012.
• Campbell J, McQueen RB, Corboy J, Vollmer T, Nair K. New versus old: long-term comparative effectiveness research projections for disease modifying therapies in relapsing-remitting multiple sclerosis. Abstract and poster presented at 64th Annual American Academy of Neurology meeting, New Orleans, LA April 26, 2012.
• 100. Vollmer T, Due B. A double-blind, placebo-controlled, phase2, 26-week DreaMS trial of a selective S1P receptor agnonists ONO 4641 in patients with relapsing-remitting multiple sclerosis. Abstract and poster presentation at the 64th Annual American Academy of Neurology meeting, New Orleans, LA, April 25, 2012
• Schwartz CE, Bode RK, Vollmer TL. The symptom inventory disability-specific short forms for multiple sclerosis: Construct validity and responsiveness, and interpretation. Archives of Physical Medicine and Rehabilitation, 2012 (pending)
• Campbell J, McQueen RB, Miravalle A, Corboy J, Vollmer T, Nair K. Comparative effectiveness of early natalizumab treatment in JCV negative relapsing-remitting MS. Submitted to Neurology Jan. 2012
• Schwartz, CE, Snook, E, Quaranto B, Benedict RHB, Rapkin BD, Vollmer T. Cognitive reserve and appraisal in multiple sclerosis. MS and Related Disorders under review March, 2012
• 9. Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross AH, Bar-Or A, Vollmer TL, Racke MK, Stuve O, Schwid SR, Goodman AD, Kachuck N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Ikle D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS Study. Accepted for publication in Neurology 2011.
• Kala M, Miravalle A, Vollmer T. Recent advances in mechanism of action of glateramer acetate. 2011 Journal of Neuroimmunology (accepted-in press)
• ?Return to ECTRIMS: Updates from ECTRIMS for Treatment and Research in MS? to area Neurologists, Denver, Colorado February 23, 2011.
• Vollmer, TL, Tyry, T et al. Is trigeminal neuralgia more prevalent in certain groups of multiple sclerosis patients? Poster presentation to the AAN Annual meeting, Honolulu, April, 2011.
• Fox R, Salter A, Alster JM, Cutter G, Dawson NV, Johnson S, Miller D, Tyry T, Vollmer T, Wells B, Kattan M. Do multiple sclerosis patients understand Risk? Survey results from the NARCOMS Registry. Poster presentation at the AAN annual meeting, Honolulu, Hawaii, April, 2011
• Moreau RL, Salter AR, Marrie R, Tyry T, Cutter G, Vollmer T. Comorbidities, smoking habits, and their connection with secondhand smoke. Poster presentation to the AAN annual meeting, Honolulu, Hawaii, April, 2011
• Miller D, Alster JM, Cutter G, Dawson NV, Johnson S, Kattan M, Salter A, Tyry T, Wells B, Vollmer T, Fox R. Patient preferences for information seeking and decision resources: survey results from the NARCOMS registry. Poster presentation to the AAN annual meeting, Honolulu, Hawaii, April, 2011
• Fox R, Salter A, Alster JM Dawson NV, Johnson S, Kattan M, Miller D, Tyry T, Wells B, Vollmer T, Cutter G. Risk tolerance in MS patients: survey results from the NARCOMS registry. Poster presentation to the AAN annual meeting Honolulu, Hawaii, April, 2011
• Marrie RA, Horwitz R, Cutter G, Tyry T, Vollmer T. Smokers with MS are more likely to report comorbid autoimmune diseases. Neuroepidemiology 2011;36:85-90 (doi: 10.1159/000323948)
• Schwartz CE, Sprangers MA, Oort FJ, Ahmed S, Bode R, Li Y, Vollmer T. Response shift in patients with multiple sclerosis: an application of three statistical techniques. Qual Life Res, 2011 20:10 1561-72.
• Buchanan RJ, Zuniga MA, Carrillo-Zuniga G, Chakravorty BJ, Tyry T, Moreau RL, Vollmer T. A pilot study of latinos with multiple sclerosis: demographic, disease, metnal health and psychosocial characteristics. Journal of Social Work in Disability & Rehabililtation, Nov 30, 2011, 10:4, 211-231
• Shi J, Tu JL, Gale, SD, Baxter L, Vollmer TL, Campagnolo DI, Tyry TM, Zhuang Y, Kuniyoshi SM. APOE epsilon4 is associated with exacerbation of cognitive decline in patients with multiple sclerosis. Cogn Behav Neurol 2011 24:3 128—33.
• Bomprezzi, R, Schafer R, Reese V, Misra A, Vollmer TL, Kala M. Glatiramer acetate-specific antibody itres in patients with relapsing/remitting multiple sclerosis and in experimental autoimmunte encephalitis. Scan J. Immunol. 2011 74:3 219-26.
• Vollmer TL, Robinson MR, Risser RC, Malcolm SK, Carlson JL. A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of central neuropathic pain associated with multiple sclerosis. Poster presented at the annual ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) annual meeting. Amsterdam, The Netherlands, October 21, 2011.
• Vollmer TL, Sorensen PS, Arnold DL on behalf of the BRAVO Study Group. A Placebo-Controlled and Active Comparator Phase III Trial (BRAVO) for Relapsing-Remitting Multiple Sclerosis. Poster presented at the Annual ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis)annual meeting, Amsterdam, The Netherlands on October 22, 2011.
• Nayak R, Vollmer T, Bomprezzi R, Jacolik R. A circulating biomarker for the therapeutic response in multiple sclerosis. Poster presentation ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) annual meeting in Amsterdam, The Netherlands October 21, 2011
• Bandari DS, Vollmer TL, Khatri BO, Tyry T. Assessing quality of life in patiaents with multiple sclerosis. International Journal of MS Care. 2010;12(1):34-40.
• Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology. Aug 10 2010;75(6):568-570.
• Kala M, Rhodes SN, Piao WH, Shi FD, Campagnolo DI, Vollmer TL. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol. Jan 2010;221(1):136-145.
• Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand. Sep 29 2010.
• Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. Mar 30 2010;74(13):1041-1047
• Vollmer T, Stewart T, Baxter N. Mitoxantrone and cytotoxic drugs' mechanisms of action. Neurology. Jan 5 2010;74 Suppl 1:S41-46
• Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. Apr 2010;9(4):381-390.
• Goodman AD, Brown TR, Edward KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR on behalf of the MSF204 Investigators (Vollmer TL). A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol Oct 2010;68:494-502
• Chang J, Campagnolo D, Vollmer TL, Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry. Published online Oct 9 2010. Doi: 10.1136/jnnp.2010.214924.
• Buchanan RJ, Zuniga MA, Carrillo-Zuniga G, Chakrovorty BJ, Tyry T, Moreau RL, Huang C, Vollmer T. Comparisons of Latinos, African Americans and Caucasians with multiple sclerosis. Ethnicity and Disease 2010;20 autumn:451-457.
• Marrie RA, Horwitz R, Cutter G, Tyry T, Vollmer T. Smokers with MS are more likely to report comorbid autoimmune diseases. Neuroepidemiology 2011;36:85-90 (doi: 10.1159/000323948)
• Salter AR, Cutter GR, Tyry T, Marrie RA, Vollmer T. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin. Feb 2010;26(2):493-500.
• Salter AS, Tyry T, Moreau R, Marrie RA, Vollmer T, Cutter, GR. (2010) Estimating the Probability of Employment Status Transitions and Exploration of Influential Factors. Poster presentation 2010 AAN Annual Meeting Toronto.
• Moreau R, Salter A, Tyry T, Marrie RA, Vollmer T, Cutter GR. (2010) Hand Function, Mobility and Employment Status in the NARCOMS Registry. Abstract presented at the 2010 AAN annual meeting Toronto.
• Volmer T, Bar-Or A, Campagnolo D, Panitch H, and Arnold D. (2010) Short-term Immunosuppression with Mitoxantrone Followed by Long-Term Glatiramer Acetate vs Glatiramer Acetate Alone: Results at 60 Months in Patients with Relapsing Multiple Sclerosis. Abstract,2010 American Academy of Neurology annual meeting, Toronto, Canada
• Zahir H, Moberly JB, Ford D, Truitt KE, Bar-Or A, Vollmer T. (2010) Differential effects of a selective sphingosine1-phosphate receptor 1 (S1P1) Modulator (CS-0777) on circulating lymphocyte subsets in multiple sclerosis patients. Poster presentation 2010 AAN annual meeting.
• Calabresi PA, Goodin D, Jeffrey D, Lublin FD, Rammohan K, Reder AT, Vollmer T, Stites T, Li B,Gottschalk R and Malhotra M on behalf of the FREEDOMS II Study Group. (2010) Oral fingolimod(FTY720) in relapsing-remitting multiple sclerosis: baselilne patient demographics and disease characteristics from a 2-year phase III trial (FREEDOMS II). Abstract/Poster presentation given at 2010 AAN annual meeting, Toronto; also presented at the Annual CMSC Meeting, June, 2010, San Antonio, TX
• Ramesh CN, Vollmer T, Bomprezzi R, Campagnolo D, Jacolik R. A relative deficiency in CD16+/Perforin + Lymphocytes (NK cells) in multiple sclerosis is corrected by glatiramer acetate (GA) treatment. Abstract given at ACTRIMS meeting San Antonio, TX June, 2010
• Ramesh CN, Vollmer TL, Bomprezzi R, Campagnolo D and Jocolik R. Plasma visfatin elevation in multiple Sclerosis. Abstract given at ACTRIMS meeting, San Antonio, TX June, 2010
• Marrie, RA, Cutter G, Vollmer T, and Tyry T. Physical Comorbidities Are Associated with an Increased Risk of Depression in Multiple Sclerosis. Abstract accepted, American Academy of Neurology Annual Meeting Toronto, Canada 2010.
• Marrie RA, Cutter G, Vollmer T, and Tyry T. Comorbidity is Associated with Greater Decrements in Quality of Life over Two Years in MS. Abstract #264AAN10D1 American Academy of Neurology Annual Meeting Toronto, Canada 2010
• Campagnolo, D, Bomprezzi R, Vollmer T. Recirculating phagocytes are a novel source of biomarkers for multiple sclerosis. Abstract C-99 accepted for presentation to the American Academy of Clinical Chemistry annual meeting in Anaheim, CA July, 2010
• Schmidt H, Loud S, Venkatesan A, Goins J, Frohman E, Taylor S, Sadiq S, Puccio L, Thrower B, Iski E, Riskind P, Weaver J, Bomprezzi R, Bullock B, Kinkel RP, Konkel S, Racke M, McGowan J, Vollmer T, Edward S, Steinman L, Lebus D, Greenberg B. The Accelerated Cure Project Biorepository—enabling the discovery of biomarkers in MS and other demyelinating diseases. Poster P963 presented at The Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 15th Annual conference of Rehabilitation in MS October 12—16, 2010, Gothenburg, Sweden
• Salter AR, Cofield SS, Vollmer T, Cutter GR. Timing of birth in United States-born multiple sclerosis population. Poster P617 presented at The Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 15th Annual conference of Rehabilitation in MS October 12—16, 2010, Gothenburg, Sweden
• Selmaj K, Zipp F, Bar-Or A, Miravalle A, Due B, Vollmer T. A Randomized Trial of Ceralifimod in Relapsing-Remitting Multiple Sclerosis. Submitted to Annals of Neurology Sept. 2014

Professional Memberships

• American Academy of Neurology, Member
• American Association of Immunology, Member
• American Neurological Association, Member
• American Society for Experimental NeuroTherapeutics, Member
• Consortium of Multiple Sclerosis Centers, Member
• International Society for Neuro Immunology, Member
• Society for Neuroscience, Member
• Colorado Society of Clinical Neurologists, Member

Practice Locations

• University of Colorado Hospital
• Children's Hospital Colorado

• Center for Neuroscience
• Rocky Mountain Multiple Sclerosis Center

Specialty Information

• Neurology, Board Certification (1991)
• Neuroimmunology
• NeuroImmunology Fellowship, Specialized Training (1987)

• Brain and Nervous System
• Immune System - Autoimmune Disorders
• Immune System
• Brain and Nervous System - Multiple Sclerosis